• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gelteq Launches SportsGel Brand and Signs Distribution Agreement with E-Commerce Solutions Company in Asia-Pacific Region, WPIC

    2/4/25 8:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GELS alert in real time by email

    NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announces the launch of its SportsGel brand. "SportsGel has been established to eliminate the common trade-off between performance versus taste, mouthfeel and convenience," said Nathan Givoni, Co-Founder and CEO of Gelteq. "Utilizing Gelteq's unique delivery system, SportsGel challenges the traditional sports nutrition supplement paradigm, with an improved sports performance solution tailored to the core attributes needed for each sport."

    The Company has also secured its first distribution agreement in the Asia-Pacific region for its SportsGel brand with WPIC Marketing and Technologies ("WPIC"), an Asia Pacific-focused marketing and e-commerce solutions company. WPIC was purposely chosen given its vast experience in launching and expanding many global brands into the Asia Pacific region. SportsGel's initial launch with WPIC is expected to begin with China during H1 2025 given their popular health and fitness industry. According to Statista1, China's sports nutrition market was valued at USD $6.5Billion in 2022 and is projected to grow annually at a rate of 9.1% until 2027. SportsGel will initially be launching sports-specific gels for running and cycling, as well as a functional hydration product, with plans for further product expansion in the region throughout the year.

    "Our agreement with WPIC is an essential part of our sales expansion strategy. It provides us with a direct pathway into the Asia Pacific region for our SportsGel products, with our initial foray into China representing a significant opportunity to demonstrate and validate our approach," said Mr. Givoni. "We believe that our established licensing and distribution partners will help scale the SportsGel range of products across the sports performance industry, market by market, while Gelteq continues to focus its in-house efforts on the nutraceutical and pharmaceutical industry."

    Gelteq's recently appointed Head of Sports Performance, Matthew Jones, will oversee all the SportsGel formulations, which will be available to license for companies interested in Gelteq's proprietary delivery system as a key differentiator in the sports nutrition space.

    About Gelteq Limited:

    Headquartered in Melbourne, Australia, Gelteq (NASDAQ:GELS) is a global biotechnology company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. Gelteq advances and commercializes its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. The Company's unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com.

    About WPIC Marketing + Technologies:

    WPIC Marketing + Technologies drives growth for global brands in China, Japan, South Korea, and Southeast Asia through e-commerce solutions, strategic brand development, data analytics, marketing, logistics, compliance, essential support services, and more. With a team of over 400 full-time e-commerce professionals, WPIC has successfully deployed and grown over 650+ brands across APAC.

    Forward-Looking Statements 

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "suggest," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq's products, the success of new programs and the ability to successfully implement a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in the Annual Report on 20-F filed on November 15, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.

    Contact:

    CORE IR

    516-222-2560

    [email protected]

    ______________________

    1 Statista. (2023). "Sports Nutrition Market in China - Statistics & Facts."



    Primary Logo

    Get the next $GELS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GELS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GELS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Wynne Paul Michael

    3 - Gelteq Ltd (0001920092) (Issuer)

    3/18/26 8:17:20 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Szewach Simon H

    3 - Gelteq Ltd (0001920092) (Issuer)

    3/18/26 8:16:29 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Karp Bradley Glenn

    3 - Gelteq Ltd (0001920092) (Issuer)

    3/18/26 7:18:40 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    SEC Filings

    View All

    SEC Form 6-K filed by Gelteq Limited

    6-K - Gelteq Ltd (0001920092) (Filer)

    3/24/26 8:15:06 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Gelteq Limited

    6-K - Gelteq Ltd (0001920092) (Filer)

    12/9/25 3:19:42 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 20-F filed by Gelteq Limited

    NT 20-F - Gelteq Ltd (0001920092) (Filer)

    11/3/25 5:00:53 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership

    MELBOURNE, Australia and LAS VEGAS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq") and Healthy Extracts™ Inc. ("Healthy Extracts") today announced the signing of a Memorandum of Understanding ("MoU") formalising a strategic partnership designed to accelerate the commercial rollout of next-generation gel-based nutraceutical products. The collaboration builds on Healthy Extracts' prior purchases of Gelteq-formulated products and marks the first phase of a long-term plan to bring Gelteq's proprietary gel delivery technology to large-scale US manufacturing and global distribution. Under the MoU, Healthy Extracts will leverage its established US-based nutritional manufacturing cap

    2/11/26 8:45:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform

    MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company's proprietary oral gel platform. The findings demonstrate that Gelteq's platform significantly enhances the absorption and bioavailability of cannabidiol ("CBD") compared to an existing FDA approved oil-based product. The preliminary results reinforces our platform's potential to change how medicinal cannabis is delivered and experienced by patients. Despite having

    1/13/26 9:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program

    MELBOURNE, Australia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced a new partnership with the Hong Kong Flag Football Program. The partnership will integrate Gelteq's advanced hydration and sports performance formulations into the training and competition programs of the region's men's, women's, and youth national teams. The initiative underscores the increasing interest in high-performance programs throughout the region and builds on the recently announced China-focused sales agreement with Shenzhen Mana Health Management Co. Ltd., which includes minimu

    12/16/25 9:05:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    Financials

    Live finance-specific insights

    View All

    Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand

    NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces its largest U.S. customer, Healthy Extracts (OTCQB:HYEX), has increased its initial purchase order of Gelteq collagen and Mynus sugar blocker gels by 50%, citing high demand and popularity of the products. Healthy Extracts' platform acquires, develops, patents, markets, and distributes plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar n

    12/2/24 8:30:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    Leadership Updates

    Live Leadership Updates

    View All

    Gelteq Appoints Matthew Jones as Head of Sports Performance

    NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Matthew Jones as Head of Sports Performance. He will oversee the growth, outreach, and customer strategy of Gelteq's sports vertical. "The sports industry is one of a number of key areas that Gelteq's unique formulation can pose a significant improvement to nutrient delivery over traditional methods," said Nathan Givoni, Co-Founder and CEO of Gelteq. "Matthew's pedigree aligns perfectly for this position with his global experie

    1/24/25 8:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology

    NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Dr. Paul Wynne as its Chief Scientific Officer ("CSO").  Gelteq co-founder and CEO Nathan Givoni stated, "We believe Dr. Wynne's distinguished record and expertise in formulation science and drug delivery systems will be instrumental in driving the next phase of Gelteq's product pipeline. Recognized for his collaborative approach and ability to coordinate high-performing teams that drive scientific excellence, Dr. Wynne's ped

    12/19/24 8:30:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business

    NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, announced today that it has expanded its operations in the United States with the appointment of Adam Bendell as President of U.S. Operations.   Gelteq Co-Founder and CEO Nathan Givoni stated, "The appointment of a dedicated U.S.-based President is a critical step in the execution of our growth strategy as we look to scale our operations in the U.S. market. Adam brings not only a wealth of exper

    11/12/24 9:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care